Nancy Whiting, Recludix Pharma CEO

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

As Sanofi ex­pands the reach of its block­buster Dupix­ent, the French Big Phar­ma is look­ing to go fur­ther down­stream in the IL-13 and IL-4 space with more in­flam­ma­tion and im­munol­o­gy drugs. It’s dol­ing out $125 mil­lion in up­front pay­ments to Re­cludix Phar­ma to do so.

This is Sanofi’s sec­ond pre­clin­i­cal col­lab­o­ra­tion of the week, fol­low­ing a sick­le cell dis­ease tie-up with Scribe Ther­a­peu­tics. It will work with San Diego-based Re­cludix on in­hibitors of STAT6, a tran­scrip­tion fac­tor that hits the ac­tiv­i­ty of key cy­tokines dri­ving type 2 in­flam­ma­to­ry dis­eases — name­ly IL-13 and IL-4, which are tar­get­ed by Sanofi and Re­gen­eron’s Dupix­ent.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.